The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

Inclusion Criteria

• •1. Outpatient, male or female subjects of any race, 18 years of age or higher. Female subjects of childbearing potential must have a (-) urine pregnancy test (UPT) result within 7 days of the first dose of study drug and practice a reliable method of contraception throughout the study.
• •A female is considered of childbearing potential unless she is:
• •\- postmenopausal \>5 years, without a uterus and/or both ovaries, or has been surgically sterile for \>6 months
• •Reliable methods of contraception are:
• •\- hormonal methods or intrauterine device (IUD) in use \> 90 days prior to study drug administration, barrier methods plus spermicide in use \> 14 days prior, or vasectomized partner.
• •\[Exception: Female subjects of child bearing potential (CBP) who are not sexually active are not required to practice a reliable method of contraception and may be enrolled at the Investigator's discretion provided they are counselled to remain sexually inactive for the duration of the study and understand the risks involved in getting pregnant during the study.\]
• •2. Moderate plaque type psoriasis eligible for topical therapies.
• •3. Patients with a minimum of 3% BSA to a maximum of 20% BSA \& bilateral symmetric psoriatic plaques of 2 to 4 cm in diameter.
• •4. Physician Global Assessment (PGA) score of 3.
• •5. Able to understand study requirements and sign Informed Consent/HIPAA forms.
• •\-